Iteos Therapeutics Inc (ITOS) - Net Assets
Based on the latest financial reports, Iteos Therapeutics Inc (ITOS) has net assets worth $493.80 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($623.08 Million) and total liabilities ($129.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ITOS cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $493.80 Million |
| % of Total Assets | 79.25% |
| Annual Growth Rate | 84.3% |
| 5-Year Change | 82.64% |
| 10-Year Change | N/A |
| Growth Volatility | 725.63 |
Iteos Therapeutics Inc - Net Assets Trend (2018–2024)
This chart illustrates how Iteos Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Iteos Therapeutics Inc (ITOS) total assets for the complete picture of this company's asset base.
Annual Net Assets for Iteos Therapeutics Inc (2018–2024)
The table below shows the annual net assets of Iteos Therapeutics Inc from 2018 to 2024. For live valuation and market cap data, see how much is Iteos Therapeutics Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $590.29 Million | +2.62% |
| 2023-12-31 | $575.23 Million | -13.28% |
| 2022-12-31 | $663.33 Million | +19.99% |
| 2021-12-31 | $552.82 Million | +71.05% |
| 2020-12-31 | $323.20 Million | +1962.65% |
| 2019-12-31 | $15.67 Million | +4.09% |
| 2018-12-31 | $15.05 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Iteos Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 98400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $37.00K | 0.01% |
| Other Comprehensive Income | $-16.00 Million | -2.71% |
| Other Components | $616.04 Million | 104.36% |
| Total Equity | $590.29 Million | 100.00% |
Iteos Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Iteos Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Skjern Bank A/S
CO:SKJE
|
$448.71 Million |
|
Fiverr International Ltd
NYSE:FVRR
|
$448.73 Million |
|
Thaitheparos Public Company Limited
BK:SAUCE
|
$448.84 Million |
|
GuangZhou Wahlap Technology Corporation Limited
SHE:301011
|
$448.89 Million |
|
Huang Hsiang Construction Corp
TW:2545
|
$448.64 Million |
|
Zhongtong Guomai Communication
SHG:603559
|
$448.62 Million |
|
EUROKAI GmbH & Co. KGaA
F:EUK3
|
$448.62 Million |
|
Imricor Medical Systems Inc
AU:IMR
|
$448.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Iteos Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 575,228,000 to 590,294,000, a change of 15,066,000 (2.6%).
- Net loss of 134,414,000 reduced equity.
- New share issuances of 119,994,000 increased equity.
- Other comprehensive income decreased equity by 2,759,000.
- Other factors increased equity by 32,245,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-134.41 Million | -22.77% |
| Share Issuances | $119.99 Million | +20.33% |
| Other Comprehensive Income | $-2.76 Million | -0.47% |
| Other Changes | $32.24 Million | +5.46% |
| Total Change | $- | 2.62% |
Book Value vs Market Value Analysis
This analysis compares Iteos Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.70x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 5.06x to 0.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $2.00 | $10.15 | x |
| 2019-12-31 | $1.58 | $10.15 | x |
| 2020-12-31 | $9.22 | $10.15 | x |
| 2021-12-31 | $14.63 | $10.15 | x |
| 2022-12-31 | $17.56 | $10.15 | x |
| 2023-12-31 | $16.08 | $10.15 | x |
| 2024-12-31 | $14.58 | $10.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Iteos Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -384.04%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.16x
- Recent ROE (-22.77%) is above the historical average (-37.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -119.96% | 0.00% | 0.00x | 1.82x | $-19.56 Million |
| 2019 | -143.30% | 0.00% | 0.00x | 1.96x | $-24.02 Million |
| 2020 | -11.77% | 0.00% | 0.00x | 1.07x | $-70.35 Million |
| 2021 | 38.80% | 62.22% | 0.39x | 1.60x | $159.24 Million |
| 2022 | 14.57% | 36.11% | 0.35x | 1.14x | $30.32 Million |
| 2023 | -19.58% | -894.34% | 0.02x | 1.16x | $-170.16 Million |
| 2024 | -22.77% | -384.04% | 0.05x | 1.16x | $-193.44 Million |
Industry Comparison
This section compares Iteos Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Iteos Therapeutics Inc (ITOS) | $493.80 Million | -119.96% | 0.26x | $448.68 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Iteos Therapeutics Inc
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lym… Read more